+++
title = "Neutra Life Sciences Expands Clinical Research Footprint with New Houston-Area Partnership"
date = "2025-10-13T11:05:16Z"
draft = false
summary = "Neutra Corp's subsidiary has partnered with MediNet Family Care Clinic to establish a new clinical trial site, expanding access to diverse patient populations and supporting research in chronic conditions while strengthening investor communications."
description = "Neutra Corp expands clinical research with new family medicine site in Houston area. Subsidiary Neutra Life Sciences adds MediNet clinic for Phase II/III trials in chronic conditions."
source_link = "https://www.newmediawire.com/news/neutra-corp-s-subsidiary-neutra-life-sciences-adds-to-its-site-network-with-new-joint-venture-partnership-in-family-medicine-7083364"
enclosure = "https://cdn.newsramp.app/genai/images/2510/13/0c13f6718c18f047a620b193fdf2719a.png"
article_id = 250202
feed_item_id = 22190
qrcode = "https://cdn.newsramp.app/newmediawire/qrcode/2510/13/kiwifW30.webp"
source = "NewMediaWire"
+++

<p>Neutra Corp's wholly owned subsidiary, Neutra Life Sciences, has expanded its clinical research footprint by securing a new clinical trial site partnership with MediNet Family Care Clinic, which specializes in Internal Medicine and Family Medicine. This strategic move aligns with the company's ongoing mission to grow its site management organization and bring high-quality, community-based research opportunities to diverse patient populations.</p><p>The new clinical trial site is located in a high-traffic area near the border of Sugar Land and Houston and is led by an experienced research team with a strong background in conducting clinical trials and delivering consistent, quality data. The site is fully equipped to support a wide range of protocol designs, including Phase II and III studies focused on chronic conditions such as hypertension, diabetes, hyperlipidemia, and other prevalent therapeutic areas.</p><p>Sydney Jim, CEO of Neutra Corp, stated that this new partnership represents another important step in the company's long-term strategy to grow organically and provide sponsors and contract research organizations with efficient, responsive, and high-performing research sites. By expanding into Internal Medicine and Family Medicine, the company is furthering its ability to support diverse protocols while continuing to meet the highest standards of patient care and data integrity.</p><p>The company also announced it has engaged a dedicated Investor Relations Firm to strengthen communication and transparency with shareholders and the broader investment community. This strategic move underscores the company's commitment to building lasting investor confidence, enhancing market visibility, and providing timely, accurate insights into the company's growth, performance, and strategic direction.</p><p>Neutra Life Sciences continues to experience steady growth across multiple specialties, with plans to add additional therapeutic areas in the coming quarters. Each new site is carefully selected and supported to ensure optimal performance and alignment with sponsor and CRO expectations. With this growth, Neutra Life Sciences is preparing to launch a new Diabetic Foot Ulcer trial at one of its brand-new sites in Sugar Land, Texas. For more information about the company's operations and investment opportunities, visit <a href="https://www.neutrainc.com" rel="nofollow" target="_blank">https://www.neutrainc.com</a>.</p>